Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB)
CUSIP: 034569103
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 41,587,315
- Total 13F shares
- 22,591,946
- Share change
- -26,296
- Total reported value
- $32,532,431
- Price per share
- $1.44
- Number of holders
- 18
- Value change
- -$34,513
- Number of buys
- 8
- Number of sells
- 5
Quarterly Holders Quick Answers
What is CUSIP 034569103?
CUSIP 034569103 identifies ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 034569103:
Top shareholders of ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Aron R. English |
13D/G
3/4/5
|
Director, 10%+ Owner |
51%
|
21,929,880
|
$25,877,258 | $0 | 24 Feb 2025 | |
| 22NW, LP |
13F
|
Company |
37%
|
15,467,300
|
$20,107,490 | — | 31 Mar 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
7.3%
|
3,036,325
|
$3,947,223 | — | 31 Mar 2025 | |
| MANGROVE PARTNERS IM, LLC |
13F
13D/G
|
Company |
6.2%
from 13D/G
|
2,525,252
|
$3,282,828 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.96%
|
399,219
|
$518,985 | — | 31 Mar 2025 | |
| LVW Advisors, LLC |
13F
|
Company |
0.84%
|
349,617
|
$454,503 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.49%
|
205,418
|
$267,076 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.49%
|
204,545
|
$265,909 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.38%
|
158,967
|
$206,657 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.38%
|
157,720
|
$205,036 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.12%
|
47,954
|
$62,340 | — | 31 Mar 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.06%
|
23,162
|
$30,000 | — | 31 Mar 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
18,836
|
$24,487 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.03%
|
11,169
|
$14,520 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.01%
|
5,763
|
$7,492 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
3,538
|
$4,599 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
3,448
|
$4,482 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
8
|
$10 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Mar 2025 | |
| Richard Anthony Cunningham |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
316,352
|
— | — | 04 Apr 2025 | |
| Kenneth C. Cundy |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
115,037
|
— | — | 04 Apr 2025 | |
| Simon Allen |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
70,246
|
— | — | 09 Dec 2022 | |
| Karah Herdman Parschauer |
3/4/5
|
Director |
—
class O/S missing
|
30,425
|
— | — | 21 Apr 2022 | |
| Joseph F. Lawler |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
13,236
|
— | — | 04 Apr 2025 | |
| Bimal R. Shah |
3/4/5
|
Director |
—
class O/S missing
|
6,618
|
— | — | 04 Apr 2025 | |
| Jason Aryeh |
3/4/5
|
Director |
—
class O/S missing
|
4,964
|
— | — | 04 Apr 2025 | |
| Kenneth Lin |
3/4/5
|
Director |
—
class O/S missing
|
4,964
|
— | — | 04 Apr 2025 | |
| Nathaniel Calloway |
3/4/5
|
Director |
—
class O/S missing
|
3,309
|
— | — | 04 Apr 2025 | |
| Areta Kupchyk |
3/4/5
|
Director |
—
class O/S missing
|
2,647
|
— | — | 04 Apr 2025 |
Institutional Holders of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) as of Q2 2025
As of 30 Jun 2025,
Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,591,946 shares.
The largest 10 holders included
22NW, LP, Nantahala Capital Management, LLC, MANGROVE PARTNERS IM, LLC, MORGAN STANLEY, LVW Advisors, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Ikarian Capital, LLC, MILLENNIUM MANAGEMENT LLC, and CITADEL ADVISORS LLC.
This page lists
18
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
18
Q2 2025 holders
18
Holder diff
0
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.